JP2014504147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504147A5 JP2014504147A5 JP2013535444A JP2013535444A JP2014504147A5 JP 2014504147 A5 JP2014504147 A5 JP 2014504147A5 JP 2013535444 A JP2013535444 A JP 2013535444A JP 2013535444 A JP2013535444 A JP 2013535444A JP 2014504147 A5 JP2014504147 A5 JP 2014504147A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- derivatives
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000031886 HIV Infections Diseases 0.000 claims 6
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 6
- 208000037357 HIV infectious disease Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 230000036436 anti-hiv Effects 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 229940126154 HIV entry inhibitor Drugs 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000798 anti-retroviral effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940124524 integrase inhibitor Drugs 0.000 claims 1
- 239000002850 integrase inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/913,300 US9090686B2 (en) | 2009-04-29 | 2010-10-27 | Antibodies for the treatment of HIV |
| US12/913,300 | 2010-10-27 | ||
| PCT/EP2011/068905 WO2012055980A1 (en) | 2010-10-27 | 2011-10-27 | Antibodies for the treatment of hiv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014504147A JP2014504147A (ja) | 2014-02-20 |
| JP2014504147A5 true JP2014504147A5 (enExample) | 2014-12-18 |
Family
ID=44913256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535444A Pending JP2014504147A (ja) | 2010-10-27 | 2011-10-27 | Ｈｉｖの治療用抗体 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2632953A1 (enExample) |
| JP (1) | JP2014504147A (enExample) |
| KR (1) | KR20140009174A (enExample) |
| CN (1) | CN103180342A (enExample) |
| AU (1) | AU2011322508A1 (enExample) |
| CA (1) | CA2814908A1 (enExample) |
| MX (1) | MX2013004710A (enExample) |
| RU (1) | RU2013122770A (enExample) |
| WO (1) | WO2012055980A1 (enExample) |
| ZA (1) | ZA201302639B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2961427B1 (en) * | 2013-02-28 | 2020-03-25 | Gnvie, Llc | Hiv antigens and antibodies |
| AU2014359085B2 (en) * | 2013-12-08 | 2017-11-02 | Peptcell Limited | HIV antigens and antibodies and compositions, methods and uses thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US20050002939A1 (en) * | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| MX2010012435A (es) * | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anticuerpos anti-cxcr4. |
| EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| JP2012158521A (ja) * | 2009-04-17 | 2012-08-23 | Kureha Corp | 外用剤 |
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2011
- 2011-10-27 KR KR20137011891A patent/KR20140009174A/ko not_active Withdrawn
- 2011-10-27 MX MX2013004710A patent/MX2013004710A/es unknown
- 2011-10-27 AU AU2011322508A patent/AU2011322508A1/en not_active Abandoned
- 2011-10-27 RU RU2013122770/10A patent/RU2013122770A/ru not_active Application Discontinuation
- 2011-10-27 CN CN2011800520640A patent/CN103180342A/zh active Pending
- 2011-10-27 JP JP2013535444A patent/JP2014504147A/ja active Pending
- 2011-10-27 CA CA 2814908 patent/CA2814908A1/en not_active Abandoned
- 2011-10-27 EP EP11779612.8A patent/EP2632953A1/en not_active Withdrawn
- 2011-10-27 WO PCT/EP2011/068905 patent/WO2012055980A1/en not_active Ceased
-
2013
- 2013-04-12 ZA ZA2013/02639A patent/ZA201302639B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12201857B2 (en) | Methods and compositions relating to covid antibody epitopes | |
| RU2011148077A (ru) | Антитела против cxcr4 для лечения инфекции вич | |
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| US20230192818A1 (en) | Sars-cov-2 antibodies and related compositions and methods of use | |
| JP7325166B2 (ja) | 二重特異性抗体 | |
| CN101809035B (zh) | 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白 | |
| DK2493930T3 (en) | Enhanced anti-human fractalkin antibodies and their applications. | |
| JP2012504401A5 (enExample) | ||
| JP2010532982A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| US20140121123A1 (en) | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof | |
| JP2020524991A (ja) | 二重特異性抗体を製造する方法、二重特異性抗体及びこのような抗体の治療的使用 | |
| AU2016293121A1 (en) | Antibody molecules which bind CD22 | |
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| US20230265217A1 (en) | Multispecific sars-cov-2 antibodies and methods of use | |
| JP2016516400A5 (enExample) | ||
| AU2016293118A1 (en) | Antibody molecules which bind CD45 | |
| JP2017522892A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| JP2011527579A (ja) | プロスタグランジンｅ２結合タンパク質およびこの使用 | |
| TW202126693A (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| JP2016503293A5 (enExample) | ||
| BR112019012901A2 (pt) | Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula | |
| CN113544146A (zh) | 抗pd-1结合蛋白及其使用方法 |